Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 121 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Kalra Sanjay, Baruah Manash P, Sahay Rakesh K, Unnikrishnan Ambika Gopalakrishnan, Uppal Shweta, Adetunji Omolara

Year : 2016| Volume: 20| Issue : 2 | Page no: 254-267

   This article has been cited by
 
1 Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
Lima Lawrence,Venu Menon,Sangeeta Kashyap
Current Cardiology Reports. 2018; 20(8)
[Pubmed]  [Google Scholar] [DOI]
2 Long-lasting Glucagon-like Peptide 1 Analogue Exendin-4 Ameliorates the Secretory and Synthetic Function of Islets Isolated From Severely Scalded Rats
Dongxu Zhao,Li Ma,Chuanan Shen,Dawei Li,Wenfeng Cheng,Yuru Shang,Zhaoxing Liu,Xin Wang,Kai Yin
Journal of Burn Care & Research. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes
Neil Webb,Michelle Orme,Michal Witkowski,Rie Nakanishi,Jakob Langer
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy. 2017;
[Pubmed]  [Google Scholar] [DOI]
5 Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
Ying Liu,Xia Jiang,Xin Chen
Lipids in Health and Disease. 2017; 16(1)
[Pubmed]  [Google Scholar] [DOI]
6 The role of somatostatin in GLP-1-induced inhibition of glucagon secretion in mice
Anne Ørgaard,Jens J. Holst
Diabetologia. 2017;
[Pubmed]  [Google Scholar] [DOI]
7 The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease
Carlota Recio,Francesco Maione,Asif J. Iqbal,Nicola Mascolo,Vincenzo De Feo
Frontiers in Pharmacology. 2017; 7
[Pubmed]  [Google Scholar] [DOI]
8 Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: long-term efficacy with or without rescue therapy
Philip D. Home,Bo Ahrén,Jane E.B. Reusch,Marc Rendell,Peter N. Weissman,Deborah T. Cirkel,Diane Miller,Philip Ambery,Molly C. Carr,Michael A. Nauck
Diabetes Research and Clinical Practice. 2017;
[Pubmed]  [Google Scholar] [DOI]
9 Emerging technologies to achieve oral delivery of GLP-1 and GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM)
Shengwu Ma,Liang We,Hongji Yang,Shaoping Deng,Anthony M. Jevnikar
Canadian Journal of Biotechnology. 2017; 1(1): 1
[Pubmed]  [Google Scholar] [DOI]
10 Lixisenatide: A New Option for Managing Type 2 Diabetes
Jonathan S. Newsome
Journal of Pharmacy Technology. 2017; 33(5): 195
[Pubmed]  [Google Scholar] [DOI]
11 Selective beneficial cardiometabolic effects of vertical sleeve gastrectomy are predominantly mediated through glucagon-like peptide (GLP-1) in Zucker diabetic fatty rats
Sunil Kumar,Raymond Lau,Thomas Palaia,Christopher Hall,Jenny Lee,Keneth Hall,Collin E. Brathwaite,Louis Ragolia
Annals of Medicine and Surgery. 2016; 12: 65
[Pubmed]  [Google Scholar] [DOI]

 

Read this article